• Merimepodib (VX-497): Precision Targeting of Host Nucleotide

  2026-07-06

  Explore how Merimepodib (VX-497) uniquely disrupts host nucleotide metabolism for cancer, immunosuppressive, and antiviral research. This article provides a technical deep dive and practical protocol guidance, with new insights from recent metabolic studies.

• Cimetidine: Applied Workflows for H2 Antagonist Research

  2026-07-06

  Cimetidine’s unique profile as a histamine-2 receptor antagonist and partial agonist enables advanced workflows in gastrointestinal cancer and blood-brain barrier research. This article delivers actionable protocols, troubleshooting strategies, and comparative insights to help researchers harness Cimetidine’s full experimental potential.

• A 83-01: Precision ALK-5 Inhibitor for Organoid & EMT Resear

  2026-07-05

  A 83-01 unlocks unprecedented control over TGF-β pathway dynamics, enabling precise modulation of self-renewal and differentiation in stem cell-derived organoid systems. Its selectivity and robust Smad-dependent transcription suppression make it the tool of choice for advanced EMT, cancer, and fibrosis studies.

• Antiarrhythmic Drugs and KCa2 Channel Modulation in AF Resea

  2026-07-04

  This study systematically evaluated the effects of clinically recommended antiarrhythmic agents, including dronedarone (Multaq), on small conductance calcium-activated potassium (KCa2) channels in the context of atrial fibrillation (AF) treatment. The findings clarify that most current agents, dronedarone among them, do not significantly inhibit KCa2 channels at therapeutic concentrations, underscoring the need for novel, atrial-selective pharmacological targets.

• Epalrestat: Aldose Reductase Inhibitor for Neuroprotection R

  2026-07-03

  Epalrestat stands out as a high-purity aldose reductase inhibitor enabling robust workflows for diabetic neuropathy and Parkinson’s disease models. Its unique ability to activate the KEAP1/Nrf2 pathway offers researchers an edge in oxidative stress and neuroprotection studies, with APExBIO providing rigorous quality assurance for reproducible results.

• Berberine Suppresses NLRP3 Inflammasome via SIRT6-AMPK in AF

  2026-07-03

  This study demonstrates that berberine prevents angiotensin II-induced atrial fibrillation (AF) by inhibiting NLRP3 inflammasome activation through upregulation of the SIRT6-AMPK pathway. The findings clarify a mechanistic link between metabolic signaling and cardiac inflammation, with implications for targeted AF therapies.

• DAPI (hydrochloride): Precision DNA Visualization & Workflow

  2026-07-02

  DAPI (hydrochloride) is the gold-standard fluorescent DNA stain, enabling robust chromosome and cell cycle analysis even in challenging microenvironments. This article delivers advanced workflow strategies, troubleshooting insights, and direct integration of recent mechanobiology findings to elevate experimental rigor.

• Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer to P

  2026-07-02

  Mei et al. reveal that hyperthermia-induced BRCA2 protein reduction renders BRCA2-proficient ovarian carcinoma cells sensitive to PARP inhibition, providing a strategy to overcome intrinsic resistance. Their findings support combined hyperthermia and PARP inhibitor regimens for treating a broader spectrum of ovarian cancers.

• Tetrahydromagnolol: Precision in Peripheral CB2 Receptor Ago

  2026-07-01

  Tetrahydromagnolol offers researchers a uniquely selective tool for dissecting peripheral cannabinoid receptor 2 (CB2) signaling, surpassing traditional ligands in both specificity and reproducibility. This article details optimized experimental workflows, actionable troubleshooting, and protocol enhancements that unlock the full translational potential of APExBIO’s tetrahydromagnolol in cannabinoid and anti-inflammatory research.

• Applied Workflows with 3X (DYKDDDDK) Peptide for Protein Pur

  2026-07-01

  The 3X (DYKDDDDK) Peptide streamlines high-fidelity affinity purification and immunodetection, offering unparalleled sensitivity for recombinant protein workflows. This guide delivers actionable steps, advanced troubleshooting, and evidence-driven protocol parameters to unlock robust results from bench to structural biology.

• GSK-923295: Advancing CENP-E Inhibition for Translational Im

  2026-06-30

  Explore how GSK-923295, a highly potent and selective CENP-E inhibitor, is redefining approaches to mitotic control and centromere biology in cancer research. This article integrates breakthrough mechanistic insights, strategic guidance for translational researchers, and evidence from recent high-profile studies to position GSK-923295 as a next-generation tool for dissecting chromosome alignment, mitotic arrest, and antitumor activity.

• Tetrahydromagnolol: Selective Peripheral CB2 Receptor Agonis

  2026-06-30

  Tetrahydromagnolol is a highly selective peripheral CB2 receptor agonist with 19-fold greater potency than magnolol. It demonstrates robust anti-inflammatory and analgesic mechanisms via CB2 activation, while acting as a GPR55 antagonist. This article provides evidence-backed, machine-readable benchmarking for cannabinoid receptor research and workflow integration.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus: Techni

  2026-06-29

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses reproducibility and efficiency challenges in synthesizing Cy3-labeled RNA probes for research workflows, particularly in situ hybridization and Northern blotting. It should not be used for diagnostic or therapeutic purposes, but enables researchers to generate fluorescent RNA probes with consistent labeling and yield.

• Inositol Phosphates Regulate Sin3L/Rpd3L HDAC Complex Activi

  2026-06-29

  This study reveals that inositol phosphates and specific core subunits cooperatively up-regulate the enzymatic function of the Sin3L/Rpd3L histone deacetylase (HDAC) complex. The work provides new mechanistic insights into how HDAC1/2 activity is modulated by both inducible and constitutive mechanisms, with implications for chromatin regulation and gene expression.

• Mitomycin C: Antitumor Antibiotic Optimizing Cancer Workflow

  2026-06-28

  Mitomycin C streamlines apoptosis signaling research with robust, reproducible DNA crosslinking and p53-independent apoptosis potentiation. This article decodes experimental workflows, troubleshooting strategies, and the latest translational insights to maximize the impact of this APExBIO gold-standard antitumor antibiotic.

16841 records 1/1123 page Next 12345 下5页 Last page